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Introduction
The COVID-19 (SARS-CoV-2) pandemic has 
become a reality and there is an increasing number 
of people infected and dead from COVID-19 day by 
day in Europe. At the time of publication of this study, 
there were already one million new cases and over 
50,000 deaths reported worldwide, and 2,700 and 51 in 
Poland, respectively [1]. The rapidly increasing burden 
on healthcare systems may soon be unbearable even for 
the best organized and funded ones. There is no doubt 
that in Poland, similarly to all countries, there are many 
unknowns regarding the duration of the pandemic, the 
dynamics of the increase in the number of patients re-
quiring hospitalization or intensive care and the possibil-
ity of organizational support of rapidly growing health 
care needs. Over the past month, many hospitals in our 
country have been turned into so-called uniform infec-
tious hospitals, being de facto closed for patients with 
diseases other than COVID-19. More and more cancer 
centers and units are limiting their activities due to staff 
infections or mandatory quarantine. Unfortunately, 
this situation leads to a growing problem of limited or 
complete lack of access to oncological treatment. For 
many patients diagnosed with malignant diseases, such 
a situation of indefinite duration may be tantamount to 
taking away chances for cure or a sharp deterioration in 
prognosis. There is no doubt that many patients without 
systemic anticancer treatment will have much worse 
prognosis than the vast majority of people infected with 
SARS-CoV-2. Cancer patients require special measures 
to protect them from infection and to establish diag-
nose early because the combination of both diseases 
is particularly unfavorable, not only due to the risk of 
infection-related death, but also considering, how diffi-
culty is oncological treatment of a SARS-CoV-2 positive 
individual for the patients, as well as, healthcare system. 
In response to the current situation and to safeguard 
the quality and continuity of therapy for cancer patients, 
the Polish Society of Clinical Oncology (PTOK, Polskie 
Towarzystwo Onkologii Klinicznej) has developed pre-
liminary recommendations for oncologists [2]. Due to 
the huge number of questions and requests for more 
detailed recommendations regarding specific clinical 
situations, PTOK has developed specific therapeutic 
recommendations. We would like to highlight that 
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this study does not apply to haemato-oncological and 
pediatric patients for whom the development of specific 
treatment recommendations is the responsibility of 
relevant societies. 
COVID-19 in adults with solid tumors
It is widely known that elderly people with comor-
bidities represent the population at highest risk of 
complications and death due to SARS-CoV-2 infec-
tion [3]. Since the majority (> 60%) of cancer are 
diagnosed after the age of 65, and in Poland currently 
there are about a million people diagnosed with cancer 
(including a large group undergoing active treatment), 
there is no doubt that this is a special risk population. 
Available information on the course of COVID-19 in 
cancer patients is very limited and based on 2 publica-
tions including a total of 46 patients [4, 5]. In the most 
recent publication Liang et al. analyzed the data of 
1590 patients with COVID-19 and 18 (1%) patients in 
the group had a history of cancer; this percentage was 
over 3 times higher than in the general Chinese popula-
tion (0.29%). The majority of patients included in the 
analysis were people during post-treatment follow-up, 
while 6 patients underwent active systemic therapy 
(2 — targeted therapy of lung cancer, 2 — chemo-
therapy of lung cancer, 1 — immunotherapy of clear cell 
carcinoma, 1 — complementary systemic treatment of 
breast cancer of non-specified type). Serious complica-
tions associated with COVID-19 were observed much 
more frequently in the cancer group than in the general 
population (39% vs. 8%), however, cancer patients 
were older (mean age — 63.1 vs. 48.7 years) and were 
more often smokers (22% against 7%). In lung cancer 
patients who underwent chemotherapy or surgery within 
a month before the diagnosis of COVID-19, serious 
complications were more frequent than in patients 
during long-term follow-up (75% vs. 43% respectively). 
Based on logistic regression model it was shown that 
the risk of serious complications of COVID-19 was 
greater for people with positive oncological history 
(OR = 5.39) than with chronic obstructive pulmonary 
disease (COPD; OR = 3.39), diabetes (OR = 2.2) 
and hypertension (OR = 1.87). Zhang et al. analyzed 
a group of 28 patients with solid tumors diagnosed with 
COVID-19 and treated in three hospitals in Wuhan. 
The most common cancers in the analyzed population 
were lung cancer (25%), esophageal cancer (14.3%) and 
breast cancer (10.7%), and every third patient had stage 
IV disease. All patients had previous systemic treatment 
and 21% of them received therapy within 14 days prior to 
COVID-19 diagnosis (11% chemotherapy, 7% targeted 
therapy, 4% radiotherapy, 4% immunotherapy). In most 
patients, COVID-19 symptoms appeared while at home, 
and in 29% of patients this diagnosis was made during 
hospitalization. The most common symptoms were fever 
and cough (> 80% of patients). Severe complications 
of COVID-19 were observed in the majority (70%) of 
patients with generalized cancer and in 44% of patients 
with stage I–III. COVID-19 mortality in the analyzed 
patient population was 28.6%, which is almost 10 times 
higher than in the general Chinese population [6]. 
Multifactorial analysis indicated a four times higher risk 
of serious complications in patients who underwent on-
cological treatment within 14 days before the diagnosis 
of COVID-19 (HR = 4.079; 95% CI 1.086–15.332) [5]. 
As available literature is still scarce, it is difficult to 
draw unequivocal conclusions about the risk of severe 
course of COVID-19 in patients with cancer. However, 
it seems that higher risk group includes patients with 
generalized cancer during active oncological treatment. 
Nevertheless, it is difficult to say whether the location 
of the cancer, disease stage, or the type of anti-cancer 
treatment used is more important. In Liang et al. analysis 
there were no complications observed in the only patient 
(52 years) treated for breast cancer or in 3 patients 
treated for lung cancer (patients aged 55 and 58 years 
undergoing targeted therapy; 47-year-old patient un-
dergoing chemotherapy). On the other hand, serious 
complications were observed in a 63-year-old patient 
receiving palliative chemotherapy for lung cancer and, 
surprisingly, in a 58-year-old patient undergoing im-
munotherapy for clear cell carcinoma [4]. 
Very limited scientific data does not allow to draw 
definitive conclusions regarding the principles of mana-
gement in patients diagnosed with cancer in the context 
of the SARS-CoV-2 infection risk. There is no doubt, 
however, that the age of the patients, comorbidities, and 
anti-cancer treatment may increase the risk of serious 
complications and death during COVID-19. 
Therefore, depending on the general condition of the 
patient, the nature of the planned or ongoing anti-cancer 
treatment and the clinical stage of disease, the principles 
of management  during the SARS-CoV-2 pandemic 
should be differentiated.
Recommendations for systemic 
oncological treatment
Systemic treatment of cancer patients may be ei-
ther radical (preoperative or postoperative treatment, 
chemotherapy alone in the case of chemo-sensitive 
tumors, chemotherapy in combination with irradiation) 
or palliative. We believe that it is essential to strive to 
maintain the recommended intensity of radical treat-
ment. Each time, if it is not possible to continue the 
systemic treatment already introduced with a radical 
intention, the patient must be urgently transferred to 
43
Piotr J. Wysocki et al., Systemic treatment of patients with solid tumors during the COVID-19 (SARS-CoV-2) pandemic 
another functioning clinical oncology center in a given 
province in order to continue treatment. The list of such 
centers is available through voivodship clinical oncology 
consultants. In case of palliative therapy, care should be 
taken not to remarkably deteriorate the patient’s chances 
of maintaining disease control, while reducing the expo-
sure to infectious agents; achieving this goal may require 
modification of the regimen, dosage or the drug used.
Preoperative treatment
The decision of a multidisciplinary board to initiate 
preoperative treatment always takes into account the 
planned date of surgery. For patients with breast cancer, 
when the goal of preoperative treatment is to perform 
breast-conserving surgery (especially in postmenopausal 
women [7]), it is possible to consider postponing the 
start of preoperative chemotherapy for several weeks 
and more widely use preoperative hormone therapy 
(postmenopausal patients). In patients with primarily 
operable tumors in whom preoperative chemotherapy 
has no proven effect on improving prognosis, surgery 
should be performed first, followed by systemic adjuvant 
treatment. On the other hand, in all patients with signifi-
cant local advancement of the disease, when the goal of 
neoadjuvant treatment is to achieve the possibility of sur-
gery or radical radiation therapy, the procedure should 
be started without undue delay. In patients undergoing 
preoperative chemotherapy, when significant (many 
weeks) delay of surgery is expected, it is recommended to 
consider 1–2 additional cycles of chemotherapy accord-
ing to the last used regimen. It should be ensured that 
there are no absolute contraindications for continuing 
chemotherapy (current tolerance, cumulative toxicity). If 
there are any doubts related to the possible “extension” 
of preoperative treatment, this situation could be con-
sulted with team of consultants from the Department of 
Oncology, JU-CM, Krakow (chemioterapia@su.krakow.
pl). Proposals for the management of pre/perioperative 
treatment are presented in Table 1.
Postoperative treatment
In majority of patients the initiation of systemic ad-
juvant treatment can be postponed and started within 
2 (in justified cases — 3) months after surgery. The 
exception are patients with very high risk of recurrence 
(e.g. significant local stage, triple-negative breast can-
cer). In justified clinical situations, adjuvant treatment 
may be replaced by close observation. In patients with 
hormone-dependent breast cancer (especially with low 
malignancy grade [G1] and/or low proliferative index 
[Ki67 < 30%] or with types of better prognosis), where 
the potential benefit of chemotherapy may be small, 
adjuvant hormone therapy alone should be considered. 
If there any some doubts regarding the possibility/legiti-
macy of resigning from complementary chemotherapy, it 
is possible to consult patients with the consulting team of 
the Department of Oncology, JU-CM in Krakow (che-
mioterapia@su.krakow.pl). Proposals for modification 
of adjuvant treatment are included in Table 1.
Palliative treatment
Unlike therapy with radical intention, palliative sys-
temic treatment, especially in the later lines, commonly 
based on less powerful evidence from large randomized 
clinical trials or meta-analyses. This treatment consists 
mainly of available in a given indication and active 
cytotoxic drugs used alone or in combination. In most 
cases, the way of conducting long-term, multi-stage 
palliative treatment is based on available literature 
data with relatively low scientific credibility and the 
own experience of individual oncological centers. As 
the duration and extent of the SARS-CoV-2 pandemic 
are indefinite, there is impossible to predict how long 
the implementation of exceptional rules for managing 
cancer patients will be necessary. In this context, the 
most questions regarding optimal management regard 
patients requiring chronic cancer therapy. There is no 
doubt that long-term suspension of systemic treatment 
increases the risk of disease progression, which may 
result in a significant deterioration of performance 
status and functional capacity of organs. It is therefore 
important to be aware that the long-term deterioration 
of oncological care during a pandemic can significantly 
worsen patients prognosis, to an unpredictable extent. 
For the above reasons, PTOK’s statement regard­
ing the modification of palliative treatment, in the 
situation of complete uncertainty as to the scale and 
duration of the epidemic threat, is an attempt to find 
optimal solutions that allow in the several months to 
ensure the maximum possible safety of the patient and 
disease control.
Proposed modifications of systemic treatment 
with palliative intention
 — Chemotherapy
• asymptomatic patients with good disease control 
and no risk of organ “crisis” — the possibility 
of discontinuing chemotherapy (“therapeutic 
holidays”), reducing the intensity of therapy 
(extending the intervals between courses by 
50–100%) or implementing systemic treatment 
using available oral drugs (including metronomi-
cally used) should be considered; 
• patients with deep or long-lasting remission dur-
ing maintenance chemotherapy — periodic dis-
continuation of treatment should be considered; 
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Table 1. Modification of systemic therapy regimens in radical treatment 
Management options Comment
Esophageal 
cancer
Perioperative treatment
Preferred CROSS protocol without 
modification (5 cycles of PXL 50 mg/m2 
+ CBDCA AUC 2; all cycles q1w) 
— least exposure to other patients [8] 
For adenocarcinomas of the lower 
esophagus consider perioperative 
chemotherapy without radiation 
(as in gastric cancer) 
CROSS protocol: a total of 5 + 23 RT fractions
For comparison, the PF scheme is associated with greater exposure to 
contact with other patients. PF scheme: a total of 8–10 days of inpatient 
chemotherapy + 23–28 RT fractions
Gastric 
cancer
Perioperative treatment
FLOT (4 cycles before and after surgery: 
DXL 50 mg/m2; OXA 85 mg/m2; leucovorin 
200 mg/m2; 5-FU 2600 mg/m2) q2w 
— preferred option
CAPOX (3 cycles before and after 
surgery: OXA 85 mg/m2; capecitabine 
2000 mg/m2 d1–14 or 1330 mg/m2 d1–21) 
FLOT regimen: a total of 16 days of inpatient chemotherapy — the preferred 
option with higher efficiency (the possibility of halving the length of 
hospitalization by using a home infusion device for long 5-FU infusions)
CAPOX regimen: a total of 6 outpatient chemotherapy — a less effective 
option, dedicated to patients with reduced performance status, to consider 
in patients with good performance status when no hospital beds and 
infusors are available and there is no possibility to redirect the patient to 
another center
No data on the efficacy of the FLOT regimen equivalent with capecitabine 
(only data on acceptable safety and activity in metastatic disease in phase 
I and phase II studies) — such modification is not recommended [9]
Consider a larger number of cycles in the preoperative period at the expense 
of the postoperative (e.g. 6 × FLOT → resection → 2 × FLOT) —- with the 
option of giving the entire treatment before surgery when a timely operation 
is not possible
Pancreatic 
cancer
Adjuvant chemotherapy
mFOLFIRINOX (12 cycles IRI 150 mg/m2; 
OXA 85 mg/m2; leucovorin 400 mg/m2; 
5-FU 2400 mg/m2) q2w — preferred 
option — keep the assumed dosage 
intensity [10] 
Gemcitabine (1000 mg/m2) ± capecitabine 
(1650 mg/m2) d1, 8 every 21 days
mFOLFIRINOX is the regimen of the highest effectiveness, preferred in 
patients in good performance status (PS) (it is possible to halve the length 
of hospitalization by using a home infusors device for long 5-FU infusions) 
GEM-CAP regimen is the second choice option in patients in good PS when 
no hospital beds and infusors are available and there is no possibility to 
redirect the patient to another center
In 2 retrospective studies, the benefit of adjuvant therapy was still shown 
despite its implementation > 12 weeks after resection [11, 12]
consider delaying the start of adjuvant treatment for 4 months after 
resection, especially in patients with slow recovery
HCC Non-surgical treatment
Embolization of the hepatic artery 
alone seems no less effective than 
chemoembolization or radioembolization 
— an option when appropriate pre-
parations are not available [13]
If definitive treatment (resection, embolization) is not available during 
the epidemic — sorafenib (400 mg bid) as a bridging option, preventing 
progression to the resumption of planned surgeries
Bile duct 
cancer
Adjuvant chemotherapy
Capecitabine (8 cycles 2500 mg/m2; d1– 
–14; q3w) — in case of good tolerance of 
the first 2 cycles — option of dispensing 
the medicine for 2–3 cycles and tolerance 
control via telemedicine
In patients with abnormal kidney function (CrCl 50–30 mL/min) — the 
capecitabine dose must be reduced to 75%, for CrCl < 30 mL/min — do 
not use capecitabine
Æ
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Management options Comment
Colon cancer Adjuvant chemotherapy
Shift from the Mayo regimen (5-FU bolus) 
to capecitabine, also in combination 
with radiotherapy in rectal cancer [14]. 
It is possible to dispense the medicine 
for the entire 5 weeks at once in case of 
combined radiochemotherapy 
Do not use radiochemotherapy with 
oxaliplatin in rectal cancer. This is more 
toxic and its beneficial effect on OS has 
not been proven [15]
Adjuvant chemotherapy with capecitabine 
(8 cycles 2500 mg/m2; d1–14; q3w) — in 
case of good tolerance of the first 2 cycles 
— option of dispensing the medicine 
for 2–3 cycles and tolerance control via 
telemedicine
In patients pT3 N1 consider only four 
XELOX cycles [16, 17]
The Mayo regimen is more toxic and generates more visits than treatment 
with capecitabine
Serious complications will affect no more than 20% of patients taking 
capecitabine [18]
In the stage, II consider only observation, except the patients for extremely 
poor prognosis (T4N0)
In patients with abnormal kidney function (CrCl 50–30 mL/min) — the 
capecitabine dose must be reduced to 75%, for CrCl < 30 mL/min — do 
not use capecitabine
Breast cancer Adjuvant chemotherapy
Luminal HER2-negative
• intermediate risk 
 — 4 × TC (docetaxel 
75 mg/m2 + cyclophosphamide 
600 mg/m2* q3w) [19, 20]
• high risk [21, 22]
 — 4 × ddAC** 
(q2w) → 4 × docetaxel 
75–100 mg/m2* (q3w)
 — 4 × docetaxel 75–100 mg/m2* 
(q3w) → 4 × ddAC** (q2w) 
HER2-positive
• 6 × TCH (docetaxel 
75 mg/m2 + carboplatin 
AUC6 + trastuzumab)* q3w [23]
• 4 × ddAC** (q2w) → 4 × docetaxel 
75–100 mg/m2* + trastuzumab 
(q3w) [22, 24] 
Triple-negative breast cancer (TNBC) 
• 4 × ddAC** (q2w) → 12 × paclitaxel 
80 mg/m2* (q1w)*** [22, 25]
PREDICT tool (https://breast.predict.nhs.uk/) allows you to estimate the 
benefit of chemotherapy in the context of overall survival. Considering the 
benefit against the risk of distant complications, it seems that the benefit 
up to 3–4 percentage point (p.p.) does not justify the use of chemotherapy, 
in the case of intermediate risk the benefit is usually 4–6 p.p., and at high 
risk the estimated benefit of chemotherapy exceeds 7 p.p. 
For patients with pN0–pN1 stage with a complex tumor phenotype 
(especially G2, with low or medium hormone sensitivity, borderline 
Ki67 10–40% or an unusual phenotype, e.g. G1 with high Ki67) optimal 
risk estimation is obtained using the Magee calculator (https://path.upmc.
edu/onlineTools/MageeEquations.html). It captures the percentage of Ki67 in 
tumor meshwork, the degree of differentiation with the score breakdown 
to nuclear pleomorphism, mitotic index and tubular structure (3–9 points, 
where 3–5 points correspond to G1, 6–7 points corresponds to G2, 8–9 points 
corresponds G3, Nottingham system according to Scarff-Bloom-Richardson 
modified by Elston-Ellis). Magee allows an approximate estimation of the 
Recurrence Score, which can be obtained using the Oncotype DX genomic 
test. In case of values < 11 points patients can be safely withdrawn from 
chemotherapy. In turn, the result > 25 points indicate high risk and is an 
indication for chemotherapy
Patients with ≥ pN2 stage — always belong to the highrisk group and must 
receive chemotherapy
For all triple-negative and high-risk HER2-positive and HER2-negative cancers 
(≥ pN2), adjuvant chemotherapy should be started within 30 days of surgery
Adjuvant treatment regimens recommended for use in preoperative 
chemotherapy are marked in bold
In case of high-risk, HER2-positive breast cancer adding pertuzumab to 
preoperative treatment is recommended
If paclitaxel 80 mg/m2 cannot be used weekly, docetaxel 100 mg/m2 every 
3 weeks should be given (+ long-acting growth factor [granulocyte-colony 
stimulating factor, G-CSF])
The adding of carboplatin to standard preoperative chemotherapy in patients 
with triple-negative breast cancer increases the likelihood of a pathological 
complete response (pCR) regardless of harbouring BRCA1/2 mutation. 
However, this approach increases the toxicity of chemotherapy and should 
be reserved only for patients with significant local advancement
Æ
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Table 1. cont. Modification of systemic therapy regimens in radical treatment
Lung cancer Adjuvant chemotherapy
Modified regimen PN: cisplatin  
75–80 mg/m2 + vinorelbine  
25–30 mg/m2 d1 + vinorelbine (tab) 
60 mg/m2 d8 — q3w [26]
Sequential radiochemotherapy (locally 
advanced stage) wit regimen PN: 
cisplatin 75–80 mg/m2 + vinorelbine 
25–30 mg/m2 d1 + vinorelbine (tab) 
60 mg/m2 d8 — q3w
In case of contraindications to the use of cisplatin as part of adjuvant 
postoperative chemotherapy, replacement by carboplatin is not 
recommended and patient should be only closely monitored. No literature 
data support any benefit of carboplatin in the adjuvant setting in patients 
with non-small cell lung cancer
Vinorelbine tablets can be dispensed on day 1
Gynecological 
cancers
Preoperative treatment
There are no data on the possibility 
to modify the recommended adjuvant 
treatment regimens in ovarian and 
endometrial cancer
Bladder 
cancer
Pre- or postoperative treatment
4 AMVAC courses 
— methotrexate 30 mg/m2, 
vinblastine 3 mg/m2, doxorubicin 
30 mg/m2 cisplatin 70 mg/m2 (4-hours 
infusion)** d1 — cycle repeated every 
14 days [27] 
AMVAC chemotherapy (accelerated MVAC) reserved for patients in good 
general condition (so-called fit for chemotherapy). Preferred preoperative 
treatment. In case of any doubts regarding the possibility of using 
postoperative chemotherapy — leave patients under observation
Upper urinary 
tract cancer
Adjuvant chemotherapy
4 courses with cisplatin 
70 mg/m2 + gemcitabine 
1000 mg/m2 d1, 8 every 21 days
In patients with GFR ≥ 30 and < 50 mL/min — carboplatin may be used [28]
In case of any doubts regarding the possibility of administering full 4 courses 
— leave patients under observation
If there is a need to extend the intervals between courses — the treatment 
should be discontinued [28]
*Short-acting growth factor (G-CSF); **long-acting growth factor (G-CSF); q1w — every week; q2w — every 2 weeks; q3w — every 3 weeks; bid — 2 times a day
• patients requiring maintenance of continu-
ous systemic treatment (organ “crisis” threat, 
symptoms, recently started treatment) receiving 
chemotherapy based on regimens administered 
at 3-week intervals — treatment should be con-
tinued with the chosen regimen; 
• patients receiving weekly regimens — it is rec-
ommended to modify to 2- or 3-weekly regimens 
(increase the dose of the drug) or to modify to 
doublet regimen used every 2–3 weeks. Examples 
of weekly regimens modifications are presented 
in Table 2; 
• In selected patients, with satisfactory tolerability 
and efficacy of oral chemotherapy, drugs can be 
dispensed on more than one treatment cycle. The 
prerequisite for this is the possibilit to perform 
adequate blood tests in the district outpatient 
clinic, and phone verification of results and 
subjective tolerance of therapy at the beginning 
of each course. 
 — Molecularly targeted treatment 
• patients taking oral molecularly targeted drugs 
with good previous treatment tolerance — dis-
pensing medication for a maximum of 6 months 
provided that they maintain regular remote 
contact with the attending physician and that 
there is the possibility of blood tests at the place 
of residence;
• patients receiving intravenous molecularly 
targeted drugs (mainly monoclonal antibod-
ies) — the need to maintain therapy with the 
possibility of reducing its intensity according 
to Table 3. 
 — Hormonotherapy — it is necessary to continue 
hormone therapy in accordance with standards, it 
is not recommended to stop or delay the adminis-
tration of drugs regardless of the form of their use 
(oral, intramuscular, subcutaneous). In the case of 
gonadoliberin analogues — patients should receive 
injections outside the oncological centers. 
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 — Immunotherapy with immune checkpoint inhibitors
• in patients with complete response lasting at 
least 24 months — treatment interruption 
and observation;
• in patients with objective response lasting for 
more than 6 months to consider a maximum 
2-fold extension of the intervals between courses;
• patients with stabilization or deepening re-
sponse — continuation of treatment according 
to the standards.
If there are any doubts regarding the possibility of 
dose modification, it is possible to contact the consulting 
team of the Department of Oncology, JU-CM in Krakow 
(chemioterapia@su.krakow.pl).
Neutropenic fever in the course 
of cancer treatment
Due to the fact that symptomatic SARS-CoV-2 in-
fection manifests with high fever, it is difficult to distin-
Table 2. Exemplary modifications of chemotherapy regimens in palliative treatment
Regimen Proposed modification
Paclitaxel 80 mg/m2 weekly Paclitaxel 120 mg/m2 every 2 weeks [29]
Gemcitabine 1000 mg/m2 d1, 8 every 21 days
Gemcitabine 1000 mg/m2 d1, 8, 15 every 28 days
Gemcitabine 1250 mg/m2 every 2 weeks
Gemcitabine 1000 mg/m2 every 2 weeks if there is a problem  
in maintaining the earlier dosage 
Cisplatin 25–30 mg/m2 weekly Cisplatin 50 mg/m2 every 2 weeks
Cisplatin 75 mg/m2 every 3 weeks
Cisplatin 25 mg/m2 + gemcitabine 1000 mg/m2 d1, 8 every 
21 days
Cisplatin 35 mg/m2 + gemcitabine 1250 mg/m2 every 2 weeks
Cisplatin 70 mg/m2 d1 + gemcitabine 1000 mg/m2 d1, 8, 
15 every 28 days
Vinorelbine 25 mg/m2 i.v. or 60–80 mg/m2 weekly Vinorelbine 50 mg p.o. (Monday, Wednesday, Friday) [30] or 30 mg 
p.o. every 2nd day (in the elderly) — cycles every 2–3 weeks [31, 32]
Carboplatin 2 AUC i.v. weekly Carboplatin 5–6 IV AUC every 3 weeks
Capecitabine dosage d1–14 every 21 days Capecitabine — continuous mode (66% of the standard daily dose 
for 14/21 cycle) visits every 6 weeks
Table 3. Optimization of intravenous targeted therapies use
Breast cancer Docetaxel + trastuzumab + pertuzumab Pertuzumab + trastuzumab — after 6 courses with docetaxel — dosing 
at intervals of up to 6 weeks [33, 34] (no need for loading doses) 
Trastuzumab + chemotherapy 
(different drugs)
Trastuzumab (up to every 6 weeks) + monotherapy or combinations 
of metronomically used drugs [35]
Trastuzumab emtansine Intervals up to every 6 weeks [36]
Ovarian cancer Paclitaxel + carboplatin + bevacizumab Recommended intervals up to every 4 weeks — no clear data on the 
possibility of using longer intervals [37, 38]
Colon cancer FOLFOX + panitumumab
FOLFIRI + cetuximab
Intervals up to every 4 weeks [39, 40]. In patients with an objective 
response (according to the provisions of the drug program) 
— interruption of the treatment or chemotherapy alone (without anti-
EGFR) — FOLFIRI/FOLFOX (up to every 5 weeks), alternatively capecitabine 
alone. The use of monotherapy with anti-EGFR antibodies — is less active 
than the combination of anti-EGFR antibody with 5-FU/LV [41]
FOLFIRI/FOLFOX + bevacizumab Courses every 4 weeks. The use of monotherapy with anti-VEGF 
antibodies — is less active than combination of anti-EGFR antibody 
with 5-FU/LV [42]
FOLFIRI + aflibercept Courses every 4 weeks [43]
Gastric cancer Capecitabine/5FU + cisplatin + trastuzumab Use of trastuzumab at intervals of up to 6 weeks + capecitabine 
monotherapy [44]
Renal cancer Temsirolimus There is no conclusive data on the possibility of delay — intervals of up 
to 2 weeks may be considered [45–47]
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guish the first symptoms of COVID-19 from neutropenic 
fever without performing diagnostic tests. According 
to current recommendations, patients with suspected 
COVID-19 (at least one of the symptoms: fever, cough, 
shortness of breath) should be isolated in properly 
equipped rooms (sluice room, personal protective 
equipment, pulse oximeter, thermometer, access to 
medical gases, resuscitation kit) ) and then subjected 
to further diagnostics [9]. There is no doubt that in the 
current situation every patient with symptoms sugges-
tive of COVID-19 (also with only “classic” neutropenic 
fever) can seriously disrupt the functioning of the entire 
healthcare unit and disorganize the work of medical 
staff. Therefore, in order to minimize the risk of neu-
tropenic fevers in patients undergoing chemotherapy, it 
is recommended to use prophylactically G-CSF for the 
duration of the COVID-19 (SARS-CoV-2) pandemic:
 — in all patients receiving chemotherapy at interme-
diate risk (10–20%) of neutropenic fever;
 — in all patients receiving chemotherapy, who had epi-
sode of neutropenia grade 3 according to CTC-AE 
(< 1000/mm3) during the current regimen.
Corticosteroids in premedication 
and treatment of complications
Corticosteroids in clinical oncology are most of-
ten used to prevent the side effects of chemotherapy 
(nausea, vomiting, anaphylactic reactions) or targeted 
drugs (prevention of mineralocorticoid excess syndrome 
during abiraterone acetate therapy). These drugs are 
also sometimes necessary to maximize the anti-cancer 
effect (prednisone with docetaxel in the treatment of 
castration-resistant prostate cancer or multi-drug hema-
tology regimens. In recent years, corticosteroids have also 
become the key medicines used to neutralize the auto-
immune complications of immunotherapy with immune 
checkpoint inhibitors, which often are life-threatening. 
However, since corticosteroids have a strong immuno-
suppressive effect, a lot of controversies has arisen about 
the safety of these drugs in the context of COVID-19. 
Available literature data indicate that there are no 
significant risks associated with the use of corticoste­
roids in patients infected with SARS. These drugs were 
widely used during the SARS-CoV and MERS-CoV 
epidemics [48, 49]. In a retrospective analysis of 401 criti-
cally ill patients diagnosed with SARS-CoV infection, 
corticosteroids reduced mortality and hospitalization 
time, without increasing the risk of secondary infections 
and other complications [50]. Available publications 
covering patients with MERS-CoV, SARS-CoV and 
RSV infections indicate that corticosteroids may delay 
the time of virus elimination from the body and induce 
typical complications, but have a beneficial effect on 
reducing the inflammatory process and lung tissue 
damage [48, 51]. WHO guidelines do not recommend 
routine use of corticosteroids in all patients diagnosed 
with COVID-19 [52]. According to current recommen-
dations in patients with SARS-CoV-2 infection requiring 
corticosteroids (inhaled or systemic) their administra-
tion should not be interrupted, but dose reduction may 
be considered [53]. Therefore, corticosteroids in cancer 
patients without SARS-CoV-2 infection should be used 
in accordance with medical practice. 
Patients with dyspnea without other 
clinical signs of infection
Patients reporting with dyspnea, which was not 
present before the pandemic onset, require extended 
diagnostics. If there are no other clinical symptoms 
suggestive of an infectious background, a chest CT 
scan should be performed and a SARS-CoV-2 test 
should be considered in accordance with current Chief 
Sanitary Inspector (Główny Inspektor Sanitarny, GIS) 
guidelines and the standards of health care unit. When 
radiological features suggesting interstitial pneumonia 
are present or difficult to differentiate from interstitial 
tumor involvement, a SARS-CoV-2 infection diagnostic 
should be performed and the patient should be isolated. 
In a patient without evident radiological symptoms, it 
is also important to urgently exclude the risk of pulmo-
nary embolism.
Reuse of personal protective equipment
An essential element of health care during an epi-
demic is adequate protection of both staff and patients 
against secondary infection. Currently, all healthcare 
providers in the world are facing the problem of insuf-
ficient supplies of single-use personal protective equip-
ment, and this problem especially applies to FFP2 and 
FFP3 masks. However, there are some possibilities for 
multiple use of protective masks through their appropri-
ate disinfection. Such approach is usually contrary to the 
characteristics of the discussed medical products and 
based on low-class evidence. In the current epidemio-
logical situation, however, it may be the only alternative 
that allows securing medical staff during patient care. 
Protective mask is defined as a filtering protective 
mask in the FFP2 or FFP3 class (in the US terminology 
N95 and N99, respectively). According to the current 
guidelines, protective masks are disposable medical de-
vices that should be exchanged between each individual 
contact with patient and attempts to reuse or disinfect 
them are possible only in exceptional situations, in ac-
cordance with internal hospital recommendations. 
Prolonged use is defined as the use of one protec-
tive mask without removing it between subsequent 
patients, assuming that all patients are infected with one 
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Table 4. Methods of decontamination of FFP2 and FFP3 masks
Decontamination method [55–57] Filtration efficiency/ 
/safe number of decontamination
Comment
Methods recommended by the CDC (Centers for Disease Control and Prevention) [58]
Vaporous hydrogen peroxide (VHP) High/20 Adequate infrastructure is needed
UV (sterilization chamber, 0.5–1.8 J/cm2), 
30 minutes 
High/10 Adequate infrastructure is needed
Moist heat sterilization (min. temp. 60° C 
and 80% relative humidity), 15–30 minutes
High Adequate infrastructure is needed
Other methods 
Hot air (oven), 70–75°C, 30 minutes High/20 Risk of mask deformation (depending on the 
material used)
Steam > 160°C High/3 A significant decrease in effectiveness after 
5 procedures
75% alcohol, wetting and drying Ineffective The method should not be used
Chlorine containing solution, 5 minutes Ineffective The method should not be used
Gamma radiation (25 cGy) No data Risk of loss of tightness, access to the cyclotron 
necessary
Microwaves (microwave oven) No data All tested masks melted during the procedure
pathogen. The maximum duration of use is difficult to 
determine — experience shows that FFP2 and FFP3 pro-
tective masks can be used for approx. 8 hours. This time 
is also preferred when protective masks are reused. 
Decontamination of protective masks in the 
FFP2 and FFP3 class is not allowed in standard situa-
tions and can only be used in emergency situations after 
it has been approved by the personnel responsible for 
the epidemiological policy. Data on the possibility of 
decontamination of protective masks are based on the 
assessment of their protective properties against patho-
gens other than SARS-CoV-2. Available data confirm 
that a temperature of 70 degrees applied for 30 minutes 
is an effective method of destroying previously tested 
forms of SARS-coronavirus [54]. It is also important, 
that viruses survival time on external surfaces is limited 
and, depending on the material, ranges from 4–72 hours.
Any method used can have a negative effect on both 
the protective properties and structure of the mask, 
which can lead to leakage, therefore, a leak test should 
be carried out after every wearing a mask. The reuse of 
masks is associated with an increased risk of infection 
in case of a decrease in filtration efficiency or incom-
plete decontamination.
Based on the data on virus survival, it is possible 
to reuse the face mask by staff after a downtime of 
5 days. In this situation, each employee exposed to the 
virus receives 5 masks signed with their name, each of 
which is used for 1 day, and then stored in a paper bag 
for 5 days. If there are not enough masks, it is possible to 
consider one of the decontamination methods (Table 4).
Based on the available data, the method of heat-
ing the mask for 30 minutes in the oven air heated to 
70–75°C or use of UV disinfection for 30 minutes can 
be considered as a preferred method in conditions of 
limited availability of specialized equipment. 
Summary
The recommendations of the Polish Society of Clin­
ical Oncology and their brief summary (Table 5), in the 
absence of adequate, strong scientific evidence for man­
agement during COVID­19 (SARS­CoV­2) pandemic, 
reflects the authors’ opinions. The PTOK position and 
help offered by the consultancy team of the Oncology 
Department of the Jagiellonian University­Collegium 
Medicum in Krakow are aimed at supporting deci­
sion­making clinical oncologists in this extremely 
complicated situation in which they find themselves. 
As doctors, we must remember that our own and our 
colleagues’ safety is a critical factor in the possibility of 
providing continuous care to our patients. As clinical 
oncologists, in many cases coordinating and binding 
oncological treatment, we may be forced in this ex-
traordinary situation to make extraordinary decisions, 
extraordinary commitment, extraordinary effort. At 
the same time, we must remember that we have in our 
hands the fate of the patients, in whom we cannot miss 
the chance to be completely cured, as well as of patients 
with advanced disease, in whom our decisions should 
not worsen the prognosis. 
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